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Background: The epidermal growth factor receptor (EGFR) is a potential target of anticancer therapy in gastric
cancer. However, its prognostic role in metastatic gastric or gastroesophageal junction (GE) cancer has not been
established yet.
Methods: EGFR status was analyzed by immunohistochemistry (IHC) in paraffin-embedded samples from 357
patients who received chemotherapy in 4 first-line trials. Automated RNA extraction from paraffin and
RT-quantitative PCR were additionally used to evaluate EGFR mRNA expression in 130 patients.
Results: EGFR protein expression (any grade) and overexpression (3+) were observed in 43% and 11% of patients,
respectively. EGFR positivity correlated with intestinal type histology (p = 0.05), but not with other clinicopathologic
characteristics. Median follow-up was 18.2 months. Median overall survival (OS) was similar in patients with EGFR
positive vs. those with EGFR negative tumors, regardless whether positivity was defined as ≥1+ (10.6 vs. 10.9
months, p = 0.463) or as 3+ (8.6 vs. 10.8 months, p = 0.377). The multivariate analysis indicated that EGFR status is
not an independent prognostic factor (hazard ratio 0.85, 0.56 to 1.12, p = 0.247). There were also no significant
differences in overall survival when patients were categorized according to median (p = 0.116) or quartile (p = 0.767)
distribution of EGFR mRNA gene expression. Similar distributions of progression-free survival according to EGFR
status were observed.
Conclusions: Unlike different cancer types where EGFR-positive disease is associated with an adverse prognostic
value, EGFR positivity is not prognostic of patient outcome in metastatic gastric or GE cancer.
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Despite reasonable improvement in the therapeutic
management of advanced gastric cancer with new active
regimens [1-3], the prognosis is still very limited, with a
median overall survival of approximately 9 to 11
months. With the emergence of new therapeutic
options, great effort is made in the research of biomar-
kers, which can help to identify subgroups of patients,* Correspondence: atmaca.akin@khnw.de
1Department of Hematology and Oncology, Institute of clinical research (IKF)
at Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt am Main,
Germany
Full list of author information is available at the end of the article
© 2012 Atmaca et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the orwho may benefit from special treatments. To date,
human epidermal growth factor receptor 2 (HER2) over-
expression (observed in up to 22% of patients) is the
only predictive factor, which predicts a benefit from a
treatment with the anti-HER2 antibody trastuzumab [4].
Aberrant epidermal growth factor receptor (EGFR)
signaling plays an important role in development and
progression of various human tumors. EGFR has been
demonstrated to phosphorylate and regulate numerous
cellular proteins and to initiate several signal transduc-
tion cascades, which lead to cell proliferation, migration,
invasion, metastasis, angiogenesis and inhibition of
apoptosis. While EGFR inhibitors for metastatic gastricl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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role of EGFR in gastric cancer remains controversial.
While many initial reports indicated unfavorable out-
come for EGFR protein expression or overexpression in
patients with resectable gastric cancer [5-11] some re-
cent reports could not observe a correlation between
EGFR expression and survival [12], or even found a sig-
nificant correlation of high EGFR expression with favor-
able outcome in patients with curatively resected gastric
cancer [13].
Regarding these particular controversial findings,
which are partly based on different patient populations
and different analysis methods, there is a need for clari-
fying the role of EGFR expression in a distinct setting
and well defined patient population.
To clarify the clinical relevance of EGFR status, this
study examines the clinicopathologic characteristics and
outcomes in a uniform population of Western patients
with gastric/GE junction adenocarcinoma enrolled in
first-line metastatic chemotherapy trials.
Methods
Patients
Stage IV gastric cancer patients with available tissue for
EGFR testing were indentified from a prospective data-
base of four first-line trials of chemotherapy [14-17].
Patients gave written informed consent on participa-
tion in the clinical trial and on sample collection and
analysis, which was approved by the responsible ethic
committee (ethics committee of the Landesärztekammer
Hessen, Germany). Standards of the International Con-
ference on Harmonization/ World Health Organization
(WHO) Good Clinical Practice were followed.
Pathology review
Formalin-fixed paraffin-embedded (FFPE) tumor samples
were evaluated for EGFR protein expression by immuno-
histochemistry (IHC). For each case, a corresponding
hematoxylin–eosin (H&E) section was reviewed to assess
the sample adequacy. All tumors were re-examined by a
gastrointestinal pathologist (HA) to confirm the histo-
logical subtype (diffuse vs. intestinal vs. mixed).
Immunohistochemistry
Tissue sections (5 μm thickness) were stained with H&E
or immunostained by indirect immunoperoxidase
method (DAKO, Glostrup, Denmark) as recommended
by the manufacturer. For detection of EGFR the EGFR
pharmDx TM Kit for the Dako Autostainer was used.
Tissue staining was visualized with a DAB substrate
chromogen solution. Slides were counterstained with
hematoxilin, dehydrated and mounted.
Membrane staining was evaluated in the neoplastic
cells and quantified and graded as recommended in thedetection kit (primary scoring system): 0, no staining or
membranous reactivity in <10% of tumor cells; 1+, weak,
barely perceptible membranous reactivity in > 10% of
tumor cells; 2+, complete or basolateral membranous
reactivity either non-uniform or weak in at least 10% of
cells; 3+, complete or basolateral membranous reactivity
of strong intensity in ≥10% of cells. Additionally the
following two scoring systems were also evaluated:
1.) H-Score: The score was obtained by the formula:
3 x percentage of strongly staining nuclei + 2 x per-
centage of moderately staining nuclei + percentage of
weakly staining nuclei, giving a range of 0 to 300.
Samples with score >200 were classified as positive
(overexpression) [18].
2.) Modified semiquantitative H-score: intensity of stain-
ing from 0 to 3 multiplied by the percentage of positive
tumor cells, which were categorized as 0.1 for 1-9%, 0.5
for 10-49% and 1.0 for >50% positive tumor cells. A score
>1.0 was classified as positive [19].
RNA extraction and gene expression analysis
Formalin-fixed paraffin-embedded (FFPE) tumor sam-
ples were evaluated for mRNA expression. From each
tumor block, a 5-μm section was stained with
hematoxylin–eosin and revised by a pathologist and two
consecutive 10-μm sections were cut on a standard
microtome, tumor was macro-dissected and placed into
individual tubes, and stored at 40C for ~1 month until
RNA extraction. Fully automated high-throughput RNA
extraction has been carried out according to methods
previously published [20].
Expression of EGFR and the normalization (house-
keeping) gene RPL37A was assessed by one-step RT-
quantitative PCR (qPCR). SuperScript W III Platinum W
One-Step qRT-PCR System with ROX (Invitrogen,
Karlsruhe, Germany) was used according to the manu-
facturer’s instructions. Experiments were carried out on
an ABI PRISM W7900HT (Applied Biosystems, Darm-
stadt, Germany) with 30 min at 50°C, 2 min at 95°C
followed by 40 cycles of 15 s at 95°C and 30 s at 60°C.
Relative copy numbers positively correlating with the
expression of the genes of interest were calculated by
using the 2(40-DDCT)-method. Each mRNA expression
was adjusted with the housekeeping gene. For assess-
ment of DNA contamination in RNA preparations, a
PAEP gene-specific qPCR without preceding reverse
transcription was carried out using the reagents from
the SuperScript III W Platinum W One-Step qRTPCR
System with ROX and Taq DNA Polymerase. In sam-
ples with a Cq value <35, the DNase I treatments were
repeated to prevent effects on bispecific PCR assays.
Stratagene human QPCR Reference total RNA (Strata-
gene, Waldbronn, Germany) was used as positive con-
trol for RTqPCR and human genomic DNA (Roche







ECOG performance status 0-1 326 (91)
Primary tumor location
Gastroesophageal junction/proximal stomach 107 (30)
Mid to distal stomach 231 (65)
Unclassifiable/Unknown 19 (5)
Disease status
Stage IV at diagnosis 298 (83)
z Recurrent disease 59 (17)
First-line chemotherapy
3-drug combination (FLOT) 192 (54)
2-drug combination (FLO or FLP) 165 (46)
Metastatic disease sites
Liver 157 (44)









Surgical specimen 116 (33)
Unknown 3 (1)
Primary tumor 298 (83)
Metastatic lesion 50 (14)
Unknown 9 (3)
Abbreviations: FLOT, 5-FU, leucovorin, oxaliplatin and docetaxel; FLO, 5-FU,
leucovorin, oxaliplatin; FLP, 5-FU, folic acid, cisplatin.
5-FU, Leucovorin and Oxaliplatin (FLO), 5-FU, Folic acid and Cisplatin (FLP).
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qPCR. All PCR assays were carried out in triplicate,
and the mean of triplicates was reported. Kinetic
RT-PCR was applied for the assessment of mRNA ex-
pression using the following TaqManTM-based primer/






Progression-free survival (PFS) and overall survival (OS)
were calculated by the Kaplan–Meier method, and stat-
istical significance was analyzed using the log-rank test.
To assess the univariate relationship between clinico-
pathologic variables and EGFR-status (positive or nega-
tive), the Fishers’ exact test was applied. Furthermore,
Cox proportional hazard models were used for the
multivariate analyses concerning survival times. All p




The cohort consists of 357 patients with stage IV
adenocarcinoma of middle to distal stomach (65%) or
GE junction (30%), with a similar number of Lauren’s
diffuse/mixed (48%) and intestinal tumors (39%). Liver
was the most common site of metastatic disease (44%).
The majority of samples were from primary tumor
(83%) and were biopsy specimens (67%). Patients pre-
dominantly presented with metastatic disease (83%),
and went on to receive three-drug combination
chemotherapy (54%). Table 1 summarizes patient
characteristics.
The proportion of patients randomized in four different
first-line trials with available tumor samples was 67.7%
[14], 58.3% [15], 28.7% [16], and 52.4% [17], respectively.
There was no significant difference in patients’ characteris-
tics, regarding patients with available tumor samples and
the entire study cohort.
One hundred ninety-two patients (54%) received a
three-drug regimen of oxaliplatin 85 mg/m2, leucovorin
200 mg/m2, and fluorouracil 2600 mg/m2 as a 24-hour
infusion in combination with docetaxel 50 mg/m2
(FLOT) on day 1 every 2 weeks [15-17]. One hundred
sixty-five patients (46%) received a regimen of fluoroura-
cil 2,600 mg/m2 via 24-hour infusion, leucovorin
200 mg/m2, and oxaliplatin 85 mg/m2 (FLO) every 2
weeks, or fluorouracil 2,000 mg/m2 via 24-hour infusion,
leucovorin 200 mg/m2 weekly, and cisplatin 50 mg/m2
every 2 weeks (FLP) [14].EGFR protein expression and correlation to
clinicopathologic characteristics
On IHC and according to the primary scoring system, 152
of 357 (43 %) patients tested EGFR-positive. EGFR was
negative, 1+, 2+, and 3+ in 205 (57%), 50 (14%), 62 (17%),
and 40 (11%) patients, respectively. With the modified
semiquantitative H-score, 116 (33%) patients were classi-
fied as EGFR positive (>score 1.0) and 30 (8%) patients
had an H-score of >200 (EGFR overexpression).
Table 2 summarizes EGFR positivity rate according to
baseline characteristics. The rate of EGFR positivity (any
grade) was similar between biopsies and surgical speci-
mens (41% vs 47% p = 0.538), primary tumor and
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(Lauren’s intestinal type 48% vs 37% in diffuse type,
p = 0.211), in the proximal region encompassing gastric
cardia/GE junction location and in the gastric body and
antrum (44% vs. 43%, p = 0.916) and finally according to
metastatic site (e.g. liver metastasis or not, 46% vs. 40%,
p = 0.559).
Similar associations with clinicopathologic criteria
were obtained when EGFR overexpression (EGFR 3+
group) was considered as positive, with the exception of
histological subtype. Intestinal type tumors showedTable 2 EGFR Positivity by Study Subgroup
Characteristic, n = 357 EGFR neg EGFR pos P
(score 0) (score 1-3+) Value
n (%) n (%)
Female, 143 79 (55) 64 (45)
Male, 214 126 (59) 88 (41) .69
Age,
>65, 173 96 (55) 77 (45)
≤65, 181 107 (59) 74 (41) .698
ECOG performance status,
0-1, 326 186 (57) 140 (43)
2, 22 11 (50) 11 (50) .697
Not specified, 9 8 (89) 1 (11)
Primary tumor location
Gastroesophageal junction, 107 60 (56) 47 (44)
Mid to distal stomach, 231 132 (57) 99 (43) .916
Not specified, 19 13 (68) 6 (32)
Disease status
Stage IV at diagnosis, 298 171 (57) 127 (43)
Recurrent disease, 59 34 (58) 25 (42) 1
Metastatic disease sites
Liver, present, 157 85 (54) 72 (46)
Liver, not present, 199 119 (60) 80 (40) .559
Lymph nodes, present 219 127 (58) 92 (42)
Lymph nodes, not present, 98 51 (52) 47 (48) .585
Peritoneum, present ,93 57 (61) 36 (39)
Peritoneum, not present, 263 147 (56) 116 (44) .58
Lauren classification,
Diffuse/mixed, 170 107 (63) 63 (37) .211
Intestinal, 139 72 (52) 67 (48)
Not specified, 48 26 (54) 22 (46)
Specimen used for EGFR testing
Biopsy, 238 141 (59) 97 (41)
Surgical specimen,116 62 (53) 54 (47) .538
Not specified, 3 2 (67) 1 (33)
Primary tumor, 298 173 (58) 125 (42)
Metastatic lesion, 50 24 (48) 26 (52) .418
Not specified, 9 9 (100) 0significantly higher rates of EGFR 3+ expression com-
pared with diffuse/mixed type histology (16% vs. 8%,
p = 0.05).
Correlation between EGFR protein expression and
survival
A total of 297 deaths (83%) had occurred at the time of
analysis, with median follow-up for surviving patients of
18.2 months (range 3.3 to 44.1).There was no difference
in OS and PFS between patients with EGFR positive and
negative tumors with median OS and PFS being 10.9
vs.10.6 months (p = 0.463) and 5.3 vs 5.7 months
(p = 0.185), respectively (Figure 1). There was either no
statistical difference regarding OS and PFS between the dif-
ferent EGFR + subgroups (1+ to 3+; P for trend = 0.581).
Median OS and PFS showed also no statistical differ-
ence when the modified semiquantitative H-score (>1.0
vs ≤1.0) was applied (p = 0.544 and p = 0.325, respect-
ively; data not shown). For the group with high EGFR-
expression classified by the quantiative H- score (>200),
OS and PFS also remained not statistically different from
those found in the lower expression group (p = 0.764
and p = 0.272, respectively; data not shown).
Similar distributions of OS according to EGFR status
were also observed when the survival analysis was
adjusted for the use of docetaxel (yes or no; p = 0.390)
and the type of platinum used (oxaliplatin or cisplatin;
p = 0.337).
In the multivariate analysis, including EGFR status,
age, sex, two- vs. three-drug chemotherapy, histologic
subtype, and disease status, EGFR status was not an in-
dependent predictor of overall survival (HR 0.85; p = 0.247;
Table 3). In the multivariate analysis only three-drug
chemotherapy was significantly associated with longer sur-
vival time.
Correlation between EGFR mRNA gene expression and
survival
In addition to EGFR IHC, EGFR mRNA expression was
analyzed by realtime PCR in 130 of the 357 patients.
EGFR mRNA levels correlated with protein levels in the
tumor tissue. The median mRNA expression in patients
with no EGFR protein expression was 252 copies versus
a median of 298 copies in EGFR positive patients. The
trend was also clearly visible in the different intensity
grades of EGFR IHC staining (EGFR 1+: median mRNA
288; EGFR 2+: median mRNA 264; EGFR 3+: median
mRNA 410). In line with the IHC results for protein ex-
pression, EGFR mRNA expression levels showed no sig-
nificant correlation to overall or progression free
survival. This was observed when the median was
chosen as threshold (Figure 2) or when patients were
grouped according to their quartile expression of EGFR
































Figure 1 Kaplan-Meier curves for (A) overall survival (OS) and (B) progression free survival (PFS) for patients with EGFR-positive (n = 152)
and EGFR-negative (n = 205) disease. Median OS: 10.9 vs 10.6 months, p = 0.463; median PFS: 5.3 vs 5.7 months, p = 0.185.
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Our results show that EGFR status is not prognostic of
patient outcome in metastatic gastric and GE junction
adenocarcinoma. We also found no impact of EGFR sta-
tus on progression-free survival, indicating that EGFR
overexpression is not associated with more aggressive
tumor biology or with resistance to chemotherapy in
gastric and GE junction adenocarcinoma. Our analysis is
based on a large and uniform cohort of Western patients
with metastatic gastric cancer, all treated with standar-
dized chemotherapy in a clinical trial. EGFR testing wasTable 3 Univariate and multivariate overall survival analyses
Characteristic
EGFR positive vs EGFR negative
Age >65 vs ≤65
ECOG performance status 2–3 vs 0-1
Therapy with 2- drug vs 3- drug combination
gastroesophageal junction vs Stomach
recurrent disease vs Stage IV at diagnosis
Male vs female
Liver metastasis, yes vs no
Peritoneal metastasis, yes vs no
Intestinal vs diffuse/mixed
Multivariate Overall Survival Analysis
Characteristic
EGFR positive vs EGFR negative
Age >65 vs ≤65
Therapy with 2- drug vs 3- drug combination
gastroesophageal junction vs Stomach
recurrent disease vs Stage IV at diagnosis
Male vs female
Intestinal vs. diffuse/mixed
a Univariate Overall Survival Analysis.performed according to different scoring systems and
methods (protein and mRNA gene expression) reviewed
by referenced pathologists, with other clinical and patho-
logical characteristics captured prospectively in research
databases. Unlike other studies, our cohort consists
solely of patients with stage IV disease with well anno-
tated chemotherapy data available on all of our patients,
and none received EGFR targeted therapies in the first-
or second-line setting. Our cohort is by far the largest
(n = 357) reporting on the prognostic effect of EGFR on
metastatic disease gastric cancer. Previous data fromHazard ratio (95% CI) P- value
0.91 (0.66 to 1.16) .464
1.04 (0.80 to 1.29) .747
2.13 (1.66 to 2.60) .002
0.82 (0.58 to 1.07) .117
0.69 (0.40 to 0.97) .009
0.84 (0.50 to 1.18) .326
0.92 (0.67 to 1.17) .512
1.19 (0.95 to 1.44) .163
1.26 (1.00 to 1.52) .079
0.90 (0.63 to 1.16) .43
Hazard ratio (95% CI) P- value
0.85 (0.57 to 1.13) .247
1.16 (0.88 to 1.45) .299
0.71 (0.39 to 0.97) .033
0.78 (0.43 to 1.14) .176
0.71 (0.33 to 1.10) .087
1.01 (0.71 to 1.30) .959



































Figure 2 Kaplan-Meier curves for (A) overall survival (OS) and (B) progression free survival (PFS) for patients with EGFR-mRNA >median
expression (n = 65) and EGFR-mRNA <median expression (n = 65). Median OS: 6.8 vs 10.7 months, p = 0.173; median PFS: 2.9 vs 5.9 months,
p = 0.116.
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cohorts of 86 and 43 patients and have delivered con-
flicted results regarding the prognostic value [10,21].
Regarding the curable stages, more data exist but the
prognostic role of EGFR expression in operable gastric
cancer remains controversial. Expression of EGFR in
resected gastric cancer has been linked to shorter overall
survival, more advanced tumor stage, and lymph node
metastases in some studies, but not in others [5-9,12,13].
For example, Kim et al. [13] found a correlation of EGFR
expression and improved overall survival in patients with
resected gastric cancer receiving adjuvant chemotherapy.
The controversial findings in resectable stages may
particularly derive from missing standardized procedures
and the lack of an established scoring system in the
immunohistochemical evaluation of EGFR. Besides
proper definition of the target population and tumor
characteristics, it is important to reflect distinct informa-
tion of immunohistochemical EGFR expression like in-
tensity of staining, staining pattern (focal or
homogenous), content of tumor cells and choice of pri-
mary antibodies.
Although EGFR is not a prognostic factor in meta-
static gastric cancer, this is not a reflection on its value
as a predictive marker. This is in line with recent results
from HER2, which is an established predictive factor for
treatment response to trastuzumab, while (according to
recent reports) Her2 expression itself is not a prognostic
factor in metastatic gastric cancer [4,22,23].
While no associations between Her2 expression (any
grade) and clinicopathologic criteria were seen, we found
that the rate of EGFR 3+ status was significantly asso-
ciated with intestinal type histology (intestinal, 16%; dif-
fuse, 8%; p = 0.05). The same pattern is known form
Her2 expression [4,22] and may indicate a link betweenhigh expression of the erb-receptor family and a distinct
disease biology in gastric cancer. In the TOGA-trial [4]
it was shown that the extent of Her2 expression is of
relevant predictive value. It was clearly demonstrated,
that anti HER2 treatment is only reasonable in patients
with high intensity HER2 expression (HER2 score 3+).
Whether this observation will be applicable to EGFR
inhibitors is unclear.
With emerging development of drugs interacting with
the EGF receptor or the EGFR pathway with monoclonal
antibodies like cetuximab and panitumumab, there is an
enormous need of better understanding the way of inter-
action of these drugs and the need of identifying sub-
groups of patients, who are likely to have a clinical benefit.
In the clinical setting, anti EGFR antibodies seem to
enhance the activity of chemotherapy with improved re-
sponse rates up to 60% [24]. But recently presented
results of a phase III study (REAL-3, [25]) comparing a
first-line palliative chemotherapy (epirubicin, oxaliplatin
and capecitabin) with or without the anti-EGFR antibody
panitumumab, could not demonstrate an OS/PFS benefit
or even showed a worse outcome in patients in the ex-
perimental arm.
It will be interesting if these studies could identify mo-
lecular subgroups of patients, who nevertheless could
benefit from an EGFR targeted treatment.
Conclusion
Unlike different cancer types where EGFR-positive dis-
ease is associated with an adverse prognostic value,
EGFR positivity is not prognostic of patient outcome in
metastatic gastric or GE cancer.
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